864245-57-8 Usage
Description
E7050 intermediate is a compound utilized in the synthesis of E7050, a small molecule kinase inhibitor with potential anti-cancer and anti-inflammatory properties. This intermediate is a critical component in the production of E7050 and represents a key step in the overall synthetic pathway. Although the exact chemical structure and properties of the intermediate are not publicly disclosed, it is recognized as an essential element in the manufacturing process of this promising therapeutic agent.
Usage:
Used in Pharmaceutical Industry:
E7050 intermediate is used as a key component in the synthesis of E7050, a small molecule kinase inhibitor, for its potential anti-cancer and anti-inflammatory properties. It plays a crucial role in the production process, enabling the development of this promising therapeutic agent.
Check Digit Verification of cas no
The CAS Registry Mumber 864245-57-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,4,2,4 and 5 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 864245-57:
(8*8)+(7*6)+(6*4)+(5*2)+(4*4)+(3*5)+(2*5)+(1*7)=188
188 % 10 = 8
So 864245-57-8 is a valid CAS Registry Number.
864245-57-8Relevant articles and documents
MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF
-
Page/Page column 84, (2019/12/25)
Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutica
KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES
-
Page/Page column 41, (2008/06/13)
The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.
Monocyclic heterocycles as kinase inhibitors
-
Page/Page column 92, (2008/06/13)
The present invention is directed to compounds having the formula and methods for using them for the treatment of cancer.
